Recent Progress and Development of Small Molecule Kinase Inhibitors for the Treatment of Breast Cancer

DeSantis, C.E.; Ma, J.; Gaudet, M.M.; Newman, L.A.; Miller, K.D.; Goding Sauer, A.; Jemal, A.; Siegel, R.L. Breast cancer statistics, 2019. CA Cancer J. Clin., 2019, 69(6), 438-451.
[PMID: 31577379]

Dai, X.; Li, T.; Bai, Z.; Yang, Y.; Liu, X.; Zhan, J.; Shi, B. Breast cancer intrinsic subtype classification, clinical use and future trends. Am. J. Cancer Res., 2015, 5(10), 2929-2943.
[PMID: 26693050]

Dawood, S. Triple-negative breast cancer: epidemiology and management options. Drugs, 2010, 70(17), 2247-2258.
[PMID: 21080741]

Tamimi, R.M.; Colditz, G.A.; Hazra, A.; Baer, H.J.; Hankinson, S.E.; Rosner, B.; Marotti, J.; Connolly, J.L.; Schnitt, S.J.; Collins, L.C. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res. Treat., 2012, 131(1), 159-167.
[PMID: 21830014]

Lin, N.U.; Winer, E.P. Brain metastases: the HER2 paradigm. Clin. Cancer Res., 2007, 13(6), 1648-1655.
[PMID: 17363517]

Martin, A.M.; Cagney, D.N.; Catalano, P.J.; Warren, L.E.; Bellon, J.R.; Punglia, R.S.; Claus, E.B.; Lee, E.Q.; Wen, P.Y.; Haas-Kogan, D.A.; Alexander, B.M.; Lin, N.U.; Aizer, A.A. Brain metastases in newly diagnosed breast cancer: a population-based study. JAMA Oncol., 2017, 3(8), 1069-1077.
[PMID: 28301662]

Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell, 2011, 144(5), 646-674.
[PMID: 21376230]

Marino, M.; Galluzzo, P.; Ascenzi, P. Estrogen signaling multiple pathways to impact gene transcription. Curr. Genomics, 2006, 7(8), 497-508.
[PMID: 18369406]

Lin, N.U.; Winer, E.P. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res., 2004, 6(5), 204-210.
[PMID: 15318926]

Ménard, S.; Fortis, S.; Castiglioni, F.; Agresti, R.; Balsari, A. HER2 as a prognostic factor in breast cancer. Oncology, 2001, 61(Suppl. 2), 67-72.
[PMID: 11694790]

Vivanco, I.; Sawyers, C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2002, 2(7), 489-501.
[PMID: 12094235]

Cantley, L.C. The phosphoinositide 3-kinase pathway. Science, 2002, 296(5573), 1655-1657.
[PMID: 12040186]

Hennessy, B.T.; Smith, D.L.; Ram, P.T.; Lu, Y.; Mills, G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov., 2005, 4(12), 988-1004.
[PMID: 16341064]

Tamura, M.; Gu, J.; Matsumoto, K.; Aota, S.; Parsons, R.; Yamada, K.M. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science, 1998, 280(5369), 1614-1617.
[PMID: 9616126]

Parsons, S.J.; Parsons, J.T. Src family kinases, key regulators of signal transduction. Oncogene, 2004, 23(48), 7906-7909.
[PMID: 15489908]

Elsberger, B. Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancer. Crit. Rev. Oncol. Hematol., 2014, 89(3), 343-351.
[PMID: 24388104]

Burotto, M.; Chiou, V.L.; Lee, J-M.; Kohn, E.C. The MAPK pathway across different malignancies: a new perspective. Cancer, 2014, 120(22), 3446-3456.
[PMID: 24948110]

Dhillon, A.S.; Hagan, S.; Rath, O.; Kolch, W. MAP kinase signalling pathways in cancer. Oncogene, 2007, 26(22), 3279-3290.
[PMID: 17496922]

Qi, X.; Yin, N.; Ma, S.; Lepp, A.; Tang, J.; Jing, W.; Johnson, B.; Dwinell, M.B.; Chitambar, C.R.; Chen, G. p38γ MAPK is a therapeutic target for triple-negative breast cancer by stimulation of cancer stem-like cell expansion. Stem Cells, 2015, 33(9), 2738-2747.
[PMID: 26077647]

Huang, S.; Wang, D.; Zhang, S.; Huang, X.; Wang, D.; Ijaz, M.; Shi, Y. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer. Cancer Chemother. Pharmacol., 2017, 80(4), 685-696.
[PMID: 28779263]

Johnson, J.; Thijssen, B.; McDermott, U.; Garnett, M.; Wessels, L.F.A.; Bernards, R. Targeting the RB-E2F pathway in breast cancer. Oncogene, 2016, 35(37), 4829-4835.
[PMID: 26923330]

Sakkiah, S.; Cao, G.P.; Gupta, S.P.; Lee, K.W. Overview of the structure and function of protein kinases. Curr. Enzym. Inhib., 2017, 13.

Singh, J.C.; Jhaveri, K.; Esteva, F.J. HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br. J. Cancer, 2014, 111(10), 1888-1898.
[PMID: 25025958]

Nielsen, D.L.; Kümler, I.; Palshof, J.A.E.; Andersson, M. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast, 2013, 22(1), 1-12.
[PMID: 23084121]

Nahta, R.; Hung, M-C.; Esteva, F.J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res., 2004, 64(7), 2343-2346.
[PMID: 15059883]

Weil, R.J.; Palmieri, D.C.; Bronder, J.L.; Stark, A.M.; Steeg, P.S. Breast cancer metastasis to the central nervous system. Am. J. Pathol., 2005, 167(4), 913-920.
[PMID: 16192626]

Swain, S.M.; Baselga, J.; Kim, S-B.; Ro, J.; Semiglazov, V.; Campone, M.; Ciruelos, E.; Ferrero, J-M.; Schneeweiss, A.; Heeson, S.; Clark, E.; Ross, G.; Benyunes, M.C.; Cortés, J. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med., 2015, 372(8), 724-734.
[PMID: 25693012]

FDA Grants Regular Approval to Pertuzumab for Adjuvant Treatment of HER2-Positive Breast Cancer.

Nelson, M.H.; Dolder, C.R. A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer. Ther. Clin. Risk Manag., 2007, 3(4), 665-673.
[PMID: 18472989]

Higa, G.M.; Abraham, J. Lapatinib in the treatment of breast cancer. Expert Rev. Anticancer Ther., 2007, 7(9), 1183-1192.
[PMID: 17892419]

Cameron, D.; Casey, M.; Press, M.; Lindquist, D.; Pienkowski, T.; Romieu, C.G.; Chan, S.; Jagiello-Gruszfeld, A.; Kaufman, B.; Crown, J.; Chan, A.; Campone, M.; Viens, P.; Davidson, N.; Gorbounova, V.; Raats, J.I.; Skarlos, D.; Newstat, B.; Roychowdhury, D.; Paoletti, P.; Oliva, C.; Rubin, S.; Stein, S.; Geyer, C.E. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat., 2008, 112(3), 533-543.
[PMID: 18188694]

Awada, A.; Colomer, R.; Inoue, K.; Bondarenko, I.; Badwe, R.A.; Demetriou, G.; Lee, S-C.; Mehta, A.O.; Kim, S-B.; Bachelot, T.; Goswami, C.; Deo, S.; Bose, R.; Wong, A.; Xu, F.; Yao, B.; Bryce, R.; Carey, L.A. Neratinib plus paclitaxel vs. trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial. JAMA Oncol., 2016, 2(12), 1557-1564.
[PMID: 27078022]

Chan, A.; Delaloge, S.; Holmes, F.A.; Moy, B.; Iwata, H.; Harvey, V.J.; Robert, N.J.; Silovski, T.; Gokmen, E.; von Minckwitz, G.; Ejlertsen, B.; Chia, S.K.L.; Mansi, J.; Barrios, C.H.; Gnant, M.; Buyse, M.; Gore, I.; Smith, J., II; Harker, G.; Masuda, N.; Petrakova, K.; Zotano, A.G.; Iannotti, N.; Rodriguez, G.; Tassone, P.; Wong, A.; Bryce, R.; Ye, Y.; Yao, B.; Martin, M. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol., 2016, 17(3), 367-377.
[PMID: 26874901]

Martin, M.; Holmes, F.A.; Ejlertsen, B.; Delaloge, S.; Moy, B.; Iwata, H.; von Minckwitz, G.; Chia, S.K.L.; Mansi, J.; Barrios, C.H.; Gnant, M.; Tomašević, Z.; Denduluri, N.; Šeparović, R.; Gokmen, E.; Bashford, A.; Ruiz Borrego, M.; Kim, S-B.; Jakobsen, E.H.; Ciceniene, A.; Inoue, K.; Overkamp, F.; Heijns, J.B.; Armstrong, A.C.; Link, J.S.; Joy, A.A.; Bryce, R.; Wong, A.; Moran, S.; Yao, B.; Xu, F.; Auerbach, A.; Buyse, M.; Chan, A.; Harvey, V.; Tomek, R.; Robert, N.J.; Gore, I.; Smith, J.W.; Masuda, N.; Di Sean Kendall, S.; Harker, W.G.; Petrakova, K.; Guerrero Zotano, A.; Simon, A.R.; Konstantinovic, Z.N.; Iannotti, N.O.; Tassone, P.; Rodriguez, G.I.; Jáñez Martinez, N.; Crespo Massieu, C.; Smickoska, S.; Somali, I.; Yilmaz, U.; Alonso, M.G.; Rosales, A.M.; Cold, S.; Knoop, A.S.; Patt, D.; Hellerstedt, B.A.; Morales Murillo, S.; Mayer, I.A.; Means-Powell, J.A.; Hui, R.; Senecal, F.M.; De Boer, R.H.; Shen, Z.; Luczak, A.A.; Chui, J.W.Y.; Tsang, J.W.; Lang, I.; Rai, Y.; Hozumi, Y.; Ten Tije, A.J.; Bhandari, M.; Osborne, C.R.C.; Ohtani, S.; Higaki, K.; Watanabe, K.; Taguchi, K.; Takahashi, M.; Filipovic, S.; Hansen, V.L.; Rao, V.P.; Gupta, M.; Petrov, P.; Coudert, B.; Vojnovic, Z.; Polya, Z.; Miyaki, T.; Yamamoto, N.; Brincat, S.; Lesniewski-Kmak, K.; Chmielowska, E.; Birhiray, R.E.; Citron, M.L.; Papish, S.W.; Berry, W.R.; Langkjer, S.T.; Garcia Sáenz, J.A.; Arance, A.M.; Efrat, N.; Sarosiek, T.; Grzeda, L.; Manalo, Y.; Smith, J.C.; Vaziri, I.; Healey, T.; Rahim, Y.; Luk, C.; Dingle, B.; Franco, S.; Sorensen, P.G.; Anand, A.; Khan, S.; Fountzilas, G.; Aogi, K.; Shimizu, S.; Mikulova, M.; Spanik, S.; Somer, R.A.; Flynn, P.J.; Coward, J.; Mainwaring, P.; Jerusalem, G.; Segura-Ojezzar, C.; Levy, C.; Delozier, T.; Khayat, D.; Coleman, R.E.; Rolles, M.J.; Maisano, R.; Nardi, M.; Ito, Y.; Yumuk, P.F.; Basaran, G.; Serdar Turhal, N.; Wilkinson, M.J.; Green, N.B.; Sidrys, A.P.; Hallmeyer, S.; Testori, D.J.; Sridhar, S.; Chang, J.; Sun, Q.; Jara-Sanchez, C.; Rubio, X.; Garrido, M.L.; De La Haba Rodriguez, J.R.; Perello Martorell, A.; Avelia Mestre, A.; Rifa Ferrer, J.; del Barco Berron, S.; Nagy, Z.; Tanaka, M. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol., 2017, 18(12), 1688-1700.
[PMID: 29146401]

Saura, C.; Oliveira, M.; Feng, Y-H.; Dai, M-S.; Hurvitz, S.A.; Kim, S-B.; Moy, B.; Delaloge, S.; Gradishar, W.J.; Masuda, N.; Palacova, M.; Trudeau, M.E.; Mattson, J.; Yap, Y.S.; Bryce, R.; Yao, B.; Bebchuk, J.D.; Keyvanjah, K.; Brufsky, A. NALA Investigators. Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with HER2+ Metastatic Breast Cancer Previously Treated with ≥ 2 HER2-Directed Regimens: Findings from the Multinational, Randomized, Phase III NALA Trial. J. Clin. Oncol., 2019, 37, 1002-1002.

Li, X.; Yang, C.; Wan, H.; Zhang, G.; Feng, J.; Zhang, L.; Chen, X.; Zhong, D.; Lou, L.; Tao, W.; Zhang, L. Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur. J. Pharm. Sci., 2017, 110, 51-61.
[PMID: 28115222]

Xu, B.; Ma, F.; Chen, S.; Li, Q.; Yang, F.; Zhang, Y.; Chen, X.; Zhong, D.; Zhang, G. A phase I study for tolerability, safety, and pharmacokinetics of pyrotinib, a novel irreversible HER2 and EGFR inhibitor, in chinese patients with HER2⁺ metastatic breast cancer. J. Clin. Oncol., 2015, 33, e11596-e11596.

Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L.R.; Padera, R.F.; Shapiro, G.I.; Baum, A.; Himmelsbach, F.; Rettig, W.J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K-K. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 2008, 27(34), 4702-4711.
[PMID: 18408761]

Minkovsky, N.; Berezov, A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr. Opin. Investig. Drugs, 2008, 9(12), 1336-1346.
[PMID: 19037840]

Cortés, J.; Dieras, V.; Ro, J.; Barriere, J.; Bachelot, T.; Hurvitz, S.; Le Rhun, E.; Espié, M.; Kim, S-B.; Schneeweiss, A.; Sohn, J.H.; Nabholtz, J-M.; Kellokumpu-Lehtinen, P-L.; Taguchi, J.; Piacentini, F.; Ciruelos, E.; Bono, P.; Ould-Kaci, M.; Roux, F.; Joensuu, H. Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncol., 2015, 16(16), 1700-1710.
[PMID: 26596672]

Moulder, S.L.; Borges, V.F.; Baetz, T.; Mcspadden, T.; Fernetich, G.; Murthy, R.K.; Chavira, R.; Guthrie, K.; Barrett, E.; Chia, S.K. Phase, I. Phase I Study of ONT-380, a HER2 inhibitor, in patients with HER2⁺-advanced solid tumors, with an expansion cohort in HER2⁺ Metastatic Breast Cancer (MBC). Clin. Cancer Res., 2017, 23(14), 3529-3536.
[PMID: 28053022]

Duchnowska, R.; Loibl, S.; Jassem, J. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer Treat. Rev., 2018, 67, 71-77.
[PMID: 29772459]

Hamilton, E.; Murthy, R.; Ferrario, C.; Conlin, A.; Krop, I.; Falkson, C.; Khan, Q.; Chamberlain, M.; Gray, T.; Borges, V. Abstract , pp. 5-20.Proceedings of the Poster Session Abstracts, 2018 , 5-

Murthy, R.; Borges, V.F.; Conlin, A.; Chaves, J.; Chamberlain, M.; Gray, T.; Vo, A.; Hamilton, E. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol., 2018, 19(7), 880-888.
[PMID: 29804905]

Das, D.; Hong, J. Irreversible kinase inhibitors targeting to cysteine residues and their applications in cancer therapy. Mini Rev. Med. Chem., 2020, 20, XXXX.

Das, D.; Hong, J. Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. Eur. J. Med. Chem., 2019, 170, 55-72.
[PMID: 30878832]

Das, D.; Xie, L.; Wang, J.; Xu, X.; Zhang, Z.; Shi, J.; Le, X.; Hong, J. Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities - Part 1. Bioorg. Med. Chem. Lett., 2019, 29(4), 591-596.
[PMID: 30600209]

Das, D.; Sikdar, P.; Bairagi, M. Recent developments of 2-aminothiazoles in medicinal chemistry. Eur. J. Med. Chem., 2016, 109, 89-98.
[PMID: 26771245]

Lombardo, L.J.; Lee, F.Y.; Chen, P.; Norris, D.; Barrish, J.C.; Behnia, K.; Castaneda, S.; Cornelius, L.A.M.; Das, J.; Doweyko, A.M.; Fairchild, C.; Hunt, J.T.; Inigo, I.; Johnston, K.; Kamath, A.; Kan, D.; Klei, H.; Marathe, P.; Pang, S.; Peterson, R.; Pitt, S.; Schieven, G.L.; Schmidt, R.J.; Tokarski, J.; Wen, M-L.; Wityak, J.; Borzilleri, R.M. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem., 2004, 47(27), 6658-6661.
[PMID: 15615512]

Das, J.; Chen, P.; Norris, D.; Padmanabha, R.; Lin, J.; Moquin, R.V.; Shen, Z.; Cook, L.S.; Doweyko, A.M.; Pitt, S.; Pang, S.; Shen, D.R.; Fang, Q.; de Fex, H.F.; McIntyre, K.W.; Shuster, D.J.; Gillooly, K.M.; Behnia, K.; Schieven, G.L.; Wityak, J.; Barrish, J.C. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J. Med. Chem., 2006, 49(23), 6819-6832.
[PMID: 17154512]

Huang, F.; Reeves, K.; Han, X.; Fairchild, C.; Platero, S.; Wong, T.W.; Lee, F.; Shaw, P.; Clark, E. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res., 2007, 67(5), 2226-2238.
[PMID: 17332353]

Finn, R.S.; Bengala, C.; Ibrahim, N.; Roché, H.; Sparano, J.; Strauss, L.C.; Fairchild, J.; Sy, O.; Goldstein, L.J. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin. Cancer Res., 2011, 17(21), 6905-6913.
[PMID: 22028489]

Green, T.P.; Fennell, M.; Whittaker, R.; Curwen, J.; Jacobs, V.; Allen, J.; Logie, A.; Hargreaves, J.; Hickinson, D.M.; Wilkinson, R.W.; Elvin, P.; Boyer, B.; Carragher, N.; Plé, P.A.; Bermingham, A.; Holdgate, G.A.; Ward, W.H.J.; Hennequin, L.F.; Davies, B.R.; Costello, G.F. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol. Oncol., 2009, 3(3), 248-261.
[PMID: 19393585]

Chen, Y.; Alvarez, E.A.; Azzam, D.; Wander, S.A.; Guggisberg, N.; Jordà, M.; Ju, Z.; Hennessy, B.T.; Slingerland, J.M. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. Breast Cancer Res. Treat., 2011, 128(1), 69-78.
[PMID: 20669046]

Kenna, M.M.; McGarrigle, S.; Pidgeon, G.P. The next Generation of PI3K-Akt-MTOR Pathway Inhibitors in Breast Cancer Cohorts. Biochimica et Biophysica Acta (BBA) -. Rev. Can., 2018, 1870, 185-197.

Furet, P.; Guagnano, V.; Fairhurst, R.A.; Imbach-Weese, P.; Bruce, I.; Knapp, M.; Fritsch, C.; Blasco, F.; Blanz, J.; Aichholz, R.; Hamon, J.; Fabbro, D.; Caravatti, G. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg. Med. Chem. Lett., 2013, 23(13), 3741-3748.
[PMID: 23726034]

Amanda Turney. FDA Approves First PI3K Inhibitor for Breast Cancer.,

Burger, M.T.; Pecchi, S.; Wagman, A.; Ni, Z-J.; Knapp, M.; Hendrickson, T.; Atallah, G.; Pfister, K.; Zhang, Y.; Bartulis, S.; Frazier, K.; Ng, S.; Smith, A.; Verhagen, J.; Haznedar, J.; Huh, K.; Iwanowicz, E.; Xin, X.; Menezes, D.; Merritt, H.; Lee, I.; Wiesmann, M.; Kaufman, S.; Crawford, K.; Chin, M.; Bussiere, D.; Shoemaker, K.; Zaror, I.; Maira, S-M.; Voliva, C.F. Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. ACS Med. Chem. Lett., 2011, 2(10), 774-779.
[PMID: 24900266]

PI3K Inhibitor Improves PFS in BELLE-2 Trial. Cancer Discov., 2016, 6(2), 115-116.
[PMID: 26681740]

D’Assoro, A.B.; Haddad, T.; Galanis, E. Aurora-A Kinase as a Promising Therapeutic Target in Cancer. Front. Oncol., 2016, 5, 295.
[PMID: 26779440]

Hole, S.; Pedersen, A.M.; Lykkesfeldt, A.E.; Yde, C.W. Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells. Breast Cancer Res. Treat., 2015, 149(3), 715-726.
[PMID: 25667100]

Cicenas, J. The Aurora kinase inhibitors in cancer research and therapy. J. Cancer Res. Clin. Oncol., 2016, 142(9), 1995-2012.
[PMID: 26932147]

Li, J.P.; Yang, Y.X.; Liu, Q.L.; Pan, S.T.; He, Z.X.; Zhang, X.; Yang, T.; Chen, X.W.; Wang, D.; Qiu, J.X.; Zhou, S.F. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells. Drug Des. Devel. Ther., 2015, 9, 1627-1652.
[PMID: 25834401]

Melichar, B.; Adenis, A.; Lockhart, A.C.; Bennouna, J.; Dees, E.C.; Kayaleh, O.; Obermannova, R.; DeMichele, A.; Zatloukal, P.; Zhang, B.; Ullmann, C.D.; Schusterbauer, C. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol., 2015, 16(4), 395-405.
[PMID: 25728526]

Niu, H.; Manfredi, M.; Ecsedy, J.A. Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer. Front. Oncol., 2015, 5, 189.
[PMID: 26380220]

Zhou, S-F.; Li, J-P.; Yang, Y.X.; Liu, Q.L.; Zhou, Z.W.; Pan, S.; He, Z.; Zhang, X.; Yang, T.; Pan, S.Y.; Duan, W.; He, S.M.; Chen, X.W.; Qiu, J. The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells. Drug Des. Devel. Ther., 2015, 9, 1027-1062.

Geffken, K.; Spiegel, S. Sphingosine kinase 1 in breast cancer. Adv. Biol. Regul., 2018, 67, 59-65.
[PMID: 29055687]

Gao, Y.; Gao, F.; Chen, K.; Tian, M.L.; Zhao, D.L. Sphingosine kinase 1 as an anticancer therapeutic target. Drug Des. Devel. Ther., 2015, 9, 3239-3245.
[PMID: 26150697]

Maczis, M.; Milstien, S.; Spiegel, S. Sphingosine-1-phosphate and estrogen signaling in breast cancer. Adv. Biol. Regul., 2016, 60, 160-165.
[PMID: 26601898]

Tsuchida, J.; Nagahashi, M.; Nakajima, M.; Moro, K.; Tatsuda, K.; Ramanathan, R.; Takabe, K.; Wakai, T. Breast cancer sphingosine-1-phosphate is associated with phospho-sphingosine kinase 1 and lymphatic metastasis. J. Surg. Res., 2016, 205(1), 85-94.
[PMID: 27621003]

Martin, J.L.; de Silva, H.C.; Lin, M.Z.; Scott, C.D.; Baxter, R.C. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. Mol. Cancer Ther., 2014, 13(2), 316-328.
[PMID: 24337110]

Datta, A.; Loo, S.Y.; Huang, B.; Wong, L.; Tan, S.S.L.; Tan, T.Z.; Lee, S-C.; Thiery, J.P.; Lim, Y.C.; Yong, W.P.; Lam, Y.; Kumar, A.P.; Yap, C.T. SPHK1 regulates proliferation and survival responses in triple-negative breast cancer. Oncotarget, 2014, 5(15), 5920-5933.
[PMID: 25153718]

Lim, K.G.; Tonelli, F.; Li, Z.; Lu, X.; Bittman, R.; Pyne, S.; Pyne, N.J. FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. J. Biol. Chem., 2011, 286(21), 18633-18640.
[PMID: 21464128]

Woo, S.M.; Seo, B.R.; Min, K.J.; Kwon, T.K. FTY720 enhances TRAIL-mediated apoptosis by up-regulating DR5 and down-regulating Mcl-1 in cancer cells. Oncotarget, 2015, 6(13), 11614-11626.
[PMID: 25843953]

Ingham, M.; Schwartz, G.K. Cell-Cycle Therapeutics Come of Age. J. Clin. Oncol., 2017, 35(25), 2949-2959.
[PMID: 28580868]

Rossi, L.; McCartney, A.; Risi, E.; De Santo, I.; Migliaccio, I.; Malorni, L.; Biganzoli, L.; Di Leo, A. Cyclin-dependent kinase 4/6 inhibitors in neoadjuvant endocrine therapy of hormone receptor-positive breast cancer. Clin. Breast Cancer, 2019, 19(6), 392-398.
[PMID: 31358432]

Murphy, C.G.; Dickler, M.N. The role of CDK4/6 inhibition in breast cancer. Oncologist, 2015, 20(5), 483-490.
[PMID: 25876993]

Asghar, U.; Witkiewicz, A.K.; Turner, N.C.; Knudsen, E.S. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat. Rev. Drug Discov., 2015, 14(2), 130-146.
[PMID: 25633797]

Dukelow, T.; Kishan, D.; Khasraw, M.; Murphy, C.G. CDK4/6 inhibitors in breast cancer. Anticancer Drugs, 2015, 26(8), 797-806.
[PMID: 26053278]

Knudsen, E.S.; Witkiewicz, A.K. The strange case of CDK4/6 inhibitors: mechanisms, resistance, and combination strategies. Trends Cancer, 2017, 3(1), 39-55.
[PMID: 28303264]

Finn, R.S.; Crown, J.P.; Lang, I.; Boer, K.; Bondarenko, I.M.; Kulyk, S.O.; Ettl, J.; Patel, R.; Pinter, T.; Schmidt, M.; Shparyk, Y.; Thummala, A.R.; Voytko, N.L.; Fowst, C.; Huang, X.; Kim, S.T.; Randolph, S.; Slamon, D.J. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol., 2015, 16(1), 25-35.
[PMID: 25524798]

Mukai, H.; Shimizu, C.; Masuda, N.; Ohtani, S.; Ohno, S.; Takahashi, M.; Yamamoto, Y.; Nishimura, R.; Sato, N.; Ohsumi, S.; Iwata, H.; Mori, Y.; Hashigaki, S.; Muramatsu, Y.; Nagasawa, T.; Umeyama, Y.; Lu, D.R.; Toi, M. Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. Int. J. Clin. Oncol., 2019, 24(3), 274-287.
[PMID: 30515674]

Verma, S.; Bartlett, C.H.; Schnell, P.; DeMichele, A.M.; Loi, S.; Ro, J.; Colleoni, M.; Iwata, H.; Harbeck, N.; Cristofanilli, M.; Zhang, K.; Thiele, A.; Turner, N.C.; Rugo, H.S. Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3). Oncologist, 2016, 21(10), 1165-1175.
[PMID: 27368881]

Finn, R.S.; Martin, M.; Rugo, H.S.; Jones, S.; Im, S.A.; Gelmon, K.; Harbeck, N.; Lipatov, O.N.; Walshe, J.M.; Moulder, S.; Gauthier, E.; Lu, D.R.; Randolph, S.; Diéras, V.; Slamon, D.J. Palbociclib and Letrozole in Advanced Breast Cancer. N. Engl. J. Med., 2016, 375(20), 1925-1936.
[PMID: 27959613]

Cristofanilli, M.; Turner, N.C.; Bondarenko, I.; Ro, J.; Im, S.A.; Masuda, N.; Colleoni, M.; DeMichele, A.; Loi, S.; Verma, S.; Iwata, H.; Harbeck, N.; Zhang, K.; Theall, K.P.; Jiang, Y.; Bartlett, C.H.; Koehler, M.; Slamon, D. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol., 2016, 17(4), 425-439.
[PMID: 26947331]

Infante, J.R.; Cassier, P.A.; Gerecitano, J.F.; Witteveen, P.O.; Chugh, R.; Ribrag, V.; Chakraborty, A.; Matano, A.; Dobson, J.R.; Crystal, A.S.; Parasuraman, S.; Shapiro, G.I. a phase i study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clin. Cancer Res., 2016, 22(23), 5696-5705.
[PMID: 27542767]

O’Shaughnessy, J.; Petrakova, K.; Sonke, G.S.; Conte, P.; Arteaga, C.L.; Cameron, D.A.; Hart, L.L.; Villanueva, C.; Jakobsen, E.; Beck, J.T.; Lindquist, D.; Souami, F.; Mondal, S.; Germa, C.; Hortobagyi, G.N. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res. Treat., 2018, 168(1), 127-134.
[PMID: 29164421]

Hortobagyi, G.N.; Stemmer, S.M.; Burris, H.A.; Yap, Y-S.; Sonke, G.S.; Paluch-Shimon, S.; Campone, M.; Blackwell, K.L.; André, F.; Winer, E.P.; Janni, W.; Verma, S.; Conte, P.; Arteaga, C.L.; Cameron, D.A.; Petrakova, K.; Hart, L.L.; Villanueva, C.; Chan, A.; Jakobsen, E.; Nusch, A.; Burdaeva, O.; Grischke, E-M.; Alba, E.; Wist, E.; Marschner, N.; Favret, A.M.; Yardley, D.; Bachelot, T.; Tseng, L-M.; Blau, S.; Xuan, F.; Souami, F.; Miller, M.; Germa, C.; Hirawat, S.; O’Shaughnessy, J. Ribociclib as first-line therapy for hr-positive, advanced breast cancer. N. Engl. J. Med., 2016, 375(18), 1738-1748.
[PMID: 27717303]

Hortobagyi, G.N.; Stemmer, S.M.; Burris, H.A.; Yap, Y.S.; Sonke, G.S.; Paluch-Shimon, S.; Campone, M.; Petrakova, K.; Blackwell, K.L.; Winer, E.P.; Janni, W.; Verma, S.; Conte, P.F.; Arteaga, C.L.; Cameron, D.A.; Xuan, F.; Miller, M.K.; Germa, C.; Hirawat, S.; O’Shaughnessy, J. Updated Results from MONALEESA-2, a Phase 3 Trial of First-Line Ribociclib + Letrozole in Hormone Receptor-Positive (HR+), HER2-Negative (HER2-), Advanced Breast Cancer (ABC). J. Clin. Oncol., 2017, 35, 1038-1038.

Slamon, D.J.; Neven, P.; Chia, S.; Fasching, P.A.; De Laurentiis, M.; Im, S.A.; Petrakova, K.; Bianchi, G.V.; Esteva, F.J.; Martín, M.; Nusch, A.; Sonke, G.S.; De la Cruz-Merino, L.; Beck, J.T.; Pivot, X.; Vidam, G.; Wang, Y.; Rodriguez Lorenc, K.; Miller, M.; Taran, T.; Jerusalem, G. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J. Clin. Oncol., 2018, 36(24), 2465-2472.
[PMID: 29860922]

Tripathy, D.; Sohn, J. Proceedings of the General Session Abstracts, 2018, pp. GS2-05.

Dickler, M.N.; Tolaney, S.M.; Rugo, H.S.; Cortés, J.; Diéras, V.; Patt, D.; Wildiers, H.; Hudis, C.A.; O’Shaughnessy, J.; Zamora, E.; Yardley, D.A.; Frenzel, M.; Koustenis, A.; Baselga, J. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR⁺/HER2^- Metastatic Breast Cancer. Clin. Cancer Res., 2017, 23(17), 5218-5224.
[PMID: 28533223]

Sledge, G.W., Jr; Toi, M.; Neven, P.; Sohn, J.; Inoue, K.; Pivot, X.; Burdaeva, O.; Okera, M.; Masuda, N.; Kaufman, P.A.; Koh, H.; Grischke, E-M.; Frenzel, M.; Lin, Y.; Barriga, S.; Smith, I.C.; Bourayou, N.; Llombart-Cussac, A. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J. Clin. Oncol., 2017, 35(25), 2875-2884.
[PMID: 28580882]

Goetz, M.P.; Toi, M.; Campone, M.; Sohn, J.; Paluch-Shimon, S.; Huober, J.; Park, I.H.; Trédan, O.; Chen, S-C.; Manso, L.; Freedman, O.C.; Garnica Jaliffe, G.; Forrester, T.; Frenzel, M.; Barriga, S.; Smith, I.C.; Bourayou, N.; Di Leo, A. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J. Clin. Oncol., 2017, 35(32), 3638-3646.
[PMID: 28968163]

Zafrakas, M.; Papasozomenou, P.; Emmanouilides, C. Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials. World J. Clin. Oncol., 2016, 7(4), 331-336.
[PMID: 27579253]

Chinchar, E.; Makey, K.L.; Gibson, J.; Chen, F.; Cole, S.A.; Megason, G.C.; Vijayakumar, S.; Miele, L.; Gu, J-W. Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells. Vasc. Cell, 2014, 6, 12.
[PMID: 24914410]

Burstein, H.J.; Elias, A.D.; Rugo, H.S.; Cobleigh, M.A.; Wolff, A.C.; Eisenberg, P.D.; Lehman, M.; Adams, B.J.; Bello, C.L.; DePrimo, S.E.; Baum, C.M.; Miller, K.D.; Phase, I.I. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol., 2008, 26(11), 1810-1816.
[PMID: 18347007]

Liljegren, A.; Bergh, J.; Castany, R. Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer. Breast, 2009, 18(4), 259-262.
[PMID: 19744626]

Bachelot, T.; Garcia-Saenz, J.A.; Verma, S.; Gutierrez, M.; Pivot, X.; Kozloff, M.F.; Prady, C.; Huang, X.; Khosravan, R.; Wang, Z.; Cesari, R.; Tassell, V.; Kern, K.A.; Blay, J-Y.; Lluch, A. Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. BMC Cancer, 2014, 14, 166.
[PMID: 24606768]

Kleibeuker, E.A.; Ten Hooven, M.A.; Verheul, H.M.; Slotman, B.J.; Thijssen, V.L. Combining radiotherapy with sunitinib: lessons (to be) learned. Angiogenesis, 2015, 18(4), 385-395.
[PMID: 26202788]

Cristofanilli, M.; Johnston, S.R.D.; Manikhas, A.; Gomez, H.L.; Gladkov, O.; Shao, Z.; Safina, S.; Blackwell, K.L.; Alvarez, R.H.; Rubin, S.D.; Ranganathan, S.; Redhu, S.; Trudeau, M.E. A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Res. Treat., 2013, 137(2), 471-482.
[PMID: 23239151]

Hu-Lowe, D.D.; Zou, H.Y.; Grazzini, M.L.; Hallin, M.E.; Wickman, G.R.; Amundson, K.; Chen, J.H.; Rewolinski, D.A.; Yamazaki, S.; Wu, E.Y.; McTigue, M.A.; Murray, B.W.; Kania, R.S.; O’Connor, P.; Shalinsky, D.R.; Bender, S.L. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res., 2008, 14(22), 7272-7283.
[PMID: 19010843]

Martin, L.P.; Kozloff, M.F.; Herbst, R.S.; Samuel, T.A.; Kim, S.; Rosbrook, B.; Tortorici, M.; Chen, Y.; Tarazi, J.; Olszanski, A.J.; Rado, T.; Starr, A.; Cohen, R.B.; Phase, I. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. Br. J. Cancer, 2012, 107(8), 1268-1276.
[PMID: 22996612]

Wang, X.; Shi, Y.; Huang, D.; Guan, X. Emerging therapeutic modalities of PARP inhibitors in breast cancer. Cancer Treat. Rev., 2018, 68, 62-68.
[PMID: 29870916]

Robson, M.; Im, S.A.; Senkus, E.; Xu, B.; Domchek, S.M.; Masuda, N.; Delaloge, S.; Li, W.; Tung, N.; Armstrong, A.; Wu, W.; Goessl, C.; Runswick, S.; Conte, P. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N. Engl. J. Med., 2017, 377(6), 523-533.
[PMID: 28578601]

Vinayak, S.; Tolaney, S.M.; Schwartzberg, L.; Mita, M.; McCann, G.; Tan, A.R.; Wahner-Hendrickson, A.E.; Forero, A.; Anders, C.; Wulf, G.M.; Dillon, P.; Lynce, F.; Zarwan, C.; Erban, J.K.; Zhou, Y.; Buerstatte, N.; Graham, J.R.; Arora, S.; Dezube, B.J.; Telli, M.L. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol., 2019, 5, 1132.
[PMID: 31194225]

Rugo, H.S.; Olopade, O.I.; DeMichele, A.; Yau, C.; van ’t Veer, L.J.; Buxton, M.B.; Hogarth, M.; Hylton, N.M.; Paoloni, M.; Perlmutter, J.; Symmans, W.F.; Yee, D.; Chien, A.J.; Wallace, A.M.; Kaplan, H.G.; Boughey, J.C.; Haddad, T.C.; Albain, K.S.; Liu, M.C.; Isaacs, C.; Khan, Q.J.; Lang, J.E.; Viscusi, R.K.; Pusztai, L.; Moulder, S.L.; Chui, S.Y.; Kemmer, K.A.; Elias, A.D.; Edmiston, K.K.; Euhus, D.M.; Haley, B.B.; Nanda, R.; Northfelt, D.W.; Tripathy, D.; Wood, W.C.; Ewing, C.; Schwab, R.; Lyandres, J.; Davis, S.E.; Hirst, G.L.; Sanil, A.; Berry, D.A.; Esserman, L.J. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N. Engl. J. Med., 2016, 375(1), 23-34.
[PMID: 27406347]

Litton, J.; Rugo, H.; Ettl, J.; Hurvitz, S.; Gonçalves, A.; Lee, K-H.; Fehrenbacher, L.; Yerushalmi, R.; Mina, L.; Martin, M.; Roché, H. Proceedings of the General Session Abstracts, 2018, pp. GS6-07.

Miller, K.; Tong, Y.; Jones, D.R.; Walsh, T.; Danso, M.A.; Ma, C.X.; Silverman, P.; King, M-C.; Badve, S.S.; Perkins, S.M. Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: final efficacy results of hoosier oncology group BRE09-146. J. Clin. Oncol., 2015, 33, 1082-1082.

Kittaneh, M.; Montero, A.J.; Glück, S. Molecular profiling for breast cancer: a comprehensive review. Biomarkers Cancer, 2013, 5, BIC.S9455